Arterial  ||| S:0 E:9 ||| JJ
stiffness  ||| S:9 E:19 ||| NN
and  ||| S:19 E:23 ||| CC
proinflammatory  ||| S:23 E:39 ||| JJ
cytokines  ||| S:39 E:49 ||| NN
in  ||| S:49 E:52 ||| IN
fibromyalgia  ||| S:52 E:65 ||| JJ
syndrome  ||| S:65 E:74 ||| NN
We  ||| S:74 E:77 ||| PRP
assessed  ||| S:77 E:86 ||| VBD
arterial  ||| S:86 E:95 ||| JJ
stiffness  ||| S:95 E:105 ||| NN
and  ||| S:105 E:109 ||| CC
inflammatory  ||| S:109 E:122 ||| JJ
cytokine  ||| S:122 E:131 ||| JJ
profiles  ||| S:131 E:140 ||| NNS
in  ||| S:140 E:143 ||| IN
fibromyalgia  ||| S:143 E:156 ||| JJ
syndrome  ||| S:156 E:165 ||| NN
( ||| S:165 E:166 ||| -LRB-
FMS ||| S:166 E:169 ||| NNP
)  ||| S:169 E:171 ||| -RRB-
patients  ||| S:171 E:180 ||| NNS
and  ||| S:180 E:184 ||| CC
analysed  ||| S:184 E:193 ||| VBG
the  ||| S:193 E:197 ||| DT
association  ||| S:197 E:209 ||| NN
between  ||| S:209 E:217 ||| IN
them ||| S:217 E:221 ||| PRP
.  ||| S:221 E:223 ||| .
Twenty-seven  ||| S:223 E:236 ||| NNP
FMS  ||| S:236 E:240 ||| NNP
patients  ||| S:240 E:249 ||| NNS
and  ||| S:249 E:253 ||| CC
29  ||| S:253 E:256 ||| CD
age-matched  ||| S:256 E:268 ||| JJ
premenopausal  ||| S:268 E:282 ||| JJ
healthy  ||| S:282 E:290 ||| JJ
controls  ||| S:290 E:299 ||| NNS
were  ||| S:299 E:304 ||| VBD
enrolled  ||| S:304 E:313 ||| VBN
in  ||| S:313 E:316 ||| IN
this  ||| S:316 E:321 ||| DT
study ||| S:321 E:326 ||| NN
.  ||| S:326 E:328 ||| .
Arterial  ||| S:328 E:337 ||| JJ
stiffness  ||| S:337 E:347 ||| NN
was  ||| S:347 E:351 ||| VBD
assessed  ||| S:351 E:360 ||| VBN
by  ||| S:360 E:363 ||| IN
pulse  ||| S:363 E:369 ||| JJ
wave  ||| S:369 E:374 ||| NN
velocity  ||| S:374 E:383 ||| NN
( ||| S:383 E:384 ||| -LRB-
PWV ||| S:384 E:387 ||| NNP
)  ||| S:387 E:389 ||| -RRB-
and  ||| S:389 E:393 ||| CC
augmentation  ||| S:393 E:406 ||| JJ
index  ||| S:406 E:412 ||| NN
( ||| S:412 E:413 ||| -LRB-
AIx ||| S:413 E:416 ||| NNP
)  ||| S:416 E:418 ||| -RRB-
from  ||| S:418 E:423 ||| IN
pulse  ||| S:423 E:429 ||| JJ
waveform  ||| S:429 E:438 ||| JJ
analysis ||| S:438 E:446 ||| NN
.  ||| S:446 E:448 ||| .
Levels  ||| S:448 E:455 ||| NNS
of  ||| S:455 E:458 ||| IN
serum  ||| S:458 E:464 ||| CD
interleukin-1β  ||| S:464 E:479 ||| CD
( ||| S:479 E:480 ||| -LRB-
IL-1β ||| S:480 E:485 ||| NNP
) ||| S:485 E:486 ||| -RRB-
,  ||| S:486 E:488 ||| ,
IL-6 ||| S:488 E:492 ||| NNP
,  ||| S:492 E:494 ||| ,
IL-8 ||| S:494 E:498 ||| NNP
,  ||| S:498 E:500 ||| ,
and  ||| S:500 E:504 ||| CC
vascular  ||| S:504 E:513 ||| JJ
endothelial  ||| S:513 E:525 ||| JJ
growth  ||| S:525 E:532 ||| NN
factor  ||| S:532 E:539 ||| NN
( ||| S:539 E:540 ||| -LRB-
VEGF ||| S:540 E:544 ||| NNP
)  ||| S:544 E:546 ||| -RRB-
were  ||| S:546 E:551 ||| VBD
measured  ||| S:551 E:560 ||| VBN
by  ||| S:560 E:563 ||| IN
enzyme-linked  ||| S:563 E:577 ||| JJ
immunosorbent  ||| S:577 E:591 ||| JJ
assay ||| S:591 E:596 ||| NN
,  ||| S:596 E:598 ||| ,
and  ||| S:598 E:602 ||| CC
a  ||| S:602 E:604 ||| DT
colorimetric  ||| S:604 E:617 ||| JJ
assay  ||| S:617 E:623 ||| NN
was  ||| S:623 E:627 ||| VBD
used  ||| S:627 E:632 ||| VBN
for  ||| S:632 E:636 ||| IN
measurement  ||| S:636 E:648 ||| NN
of  ||| S:648 E:651 ||| IN
serum  ||| S:651 E:657 ||| FW
nitric  ||| S:657 E:664 ||| FW
oxide  ||| S:664 E:670 ||| FW
( ||| S:670 E:671 ||| -LRB-
NO ||| S:671 E:673 ||| UH
)  ||| S:673 E:675 ||| -RRB-
metabolites  ||| S:675 E:687 ||| NNS
( ||| S:687 E:688 ||| -LRB-
nitrate  ||| S:688 E:696 ||| NN
and  ||| S:696 E:700 ||| CC
nitrite ||| S:700 E:707 ||| NN
,  ||| S:707 E:709 ||| ,
NOx ||| S:709 E:712 ||| NNP
)  ||| S:712 E:714 ||| -RRB-
level ||| S:714 E:719 ||| NN
.  ||| S:719 E:721 ||| .
Statistical  ||| S:721 E:733 ||| JJ
analyses  ||| S:733 E:742 ||| NNS
included  ||| S:742 E:751 ||| VBD
the  ||| S:751 E:755 ||| DT
Mann-Whitney  ||| S:755 E:768 ||| JJ
U-test  ||| S:768 E:775 ||| JJ
and  ||| S:775 E:779 ||| CC
Spearman ||| S:779 E:787 ||| NNP
's  ||| S:787 E:790 ||| POS
correlation  ||| S:790 E:802 ||| JJ
coefficient  ||| S:802 E:814 ||| JJ
analysis ||| S:814 E:822 ||| NN
.  ||| S:822 E:824 ||| .
Higher  ||| S:824 E:831 ||| RBR
AIx  ||| S:831 E:835 ||| JJ
and  ||| S:835 E:839 ||| CC
AIx ||| S:839 E:842 ||| JJ
@ ||| S:842 E:843 ||| IN
HR75  ||| S:843 E:848 ||| NNP
( ||| S:848 E:849 ||| -LRB-
aortic  ||| S:849 E:856 ||| JJ
AIx  ||| S:856 E:860 ||| NN
at  ||| S:860 E:863 ||| IN
a  ||| S:863 E:865 ||| DT
heart  ||| S:865 E:871 ||| NN
rate  ||| S:871 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
75  ||| S:879 E:882 ||| CD
beats ||| S:882 E:887 ||| CD
/ ||| S:887 E:888 ||| CD
min ||| S:888 E:891 ||| CD
)  ||| S:891 E:893 ||| -RRB-
were  ||| S:893 E:898 ||| VBD
noted  ||| S:898 E:904 ||| VBN
in  ||| S:904 E:907 ||| IN
FMS  ||| S:907 E:911 ||| NNP
compared  ||| S:911 E:920 ||| VBN
to  ||| S:920 E:923 ||| TO
those  ||| S:923 E:929 ||| DT
in  ||| S:929 E:932 ||| IN
the  ||| S:932 E:936 ||| DT
controls  ||| S:936 E:945 ||| NNS
after  ||| S:945 E:951 ||| IN
adjustment  ||| S:951 E:962 ||| NN
using  ||| S:962 E:968 ||| VBG
covariants  ||| S:968 E:979 ||| NNS
( ||| S:979 E:980 ||| -LRB-
p ||| S:980 E:981 ||| FW
( ||| S:981 E:982 ||| -LRB-
adj ||| S:982 E:985 ||| LS
) ||| S:985 E:986 ||| -RRB-
=0.023  ||| S:986 E:993 ||| NNP
and  ||| S:993 E:997 ||| CC
p ||| S:997 E:998 ||| NNS
( ||| S:998 E:999 ||| -LRB-
adj ||| S:999 E:1002 ||| LS
)  ||| S:1002 E:1003 ||| -RRB-
< ||| S:1003 E:1004 ||| SYM
0.001 ||| S:1004 E:1009 ||| CD
) ||| S:1009 E:1010 ||| -RRB-
.  ||| S:1010 E:1012 ||| .
However ||| S:1012 E:1019 ||| RB
,  ||| S:1019 E:1021 ||| ,
there  ||| S:1021 E:1027 ||| EX
were  ||| S:1027 E:1032 ||| VBD
no  ||| S:1032 E:1035 ||| DT
differences  ||| S:1035 E:1047 ||| NNS
between  ||| S:1047 E:1055 ||| IN
the  ||| S:1055 E:1059 ||| DT
three  ||| S:1059 E:1065 ||| CD
regional  ||| S:1065 E:1074 ||| JJ
PWVs  ||| S:1074 E:1079 ||| NN
of  ||| S:1079 E:1082 ||| IN
the  ||| S:1082 E:1086 ||| DT
two  ||| S:1086 E:1090 ||| CD
groups  ||| S:1090 E:1097 ||| NNS
at  ||| S:1097 E:1100 ||| IN
the  ||| S:1100 E:1104 ||| DT
aorta-femoral ||| S:1104 E:1117 ||| JJ
,  ||| S:1117 E:1119 ||| ,
femoral-dorsalis ||| S:1119 E:1135 ||| NNP
,  ||| S:1135 E:1137 ||| ,
and  ||| S:1137 E:1141 ||| CC
aorta-radialis  ||| S:1141 E:1156 ||| JJ
arteries  ||| S:1156 E:1165 ||| NNS
( ||| S:1165 E:1166 ||| -LRB-
p ||| S:1166 E:1167 ||| FW
( ||| S:1167 E:1168 ||| -LRB-
adj ||| S:1168 E:1171 ||| LS
) ||| S:1171 E:1172 ||| -RRB-
> ||| S:1172 E:1173 ||| CD
0.05  ||| S:1173 E:1178 ||| CD
for  ||| S:1178 E:1182 ||| IN
all ||| S:1182 E:1185 ||| DT
) ||| S:1185 E:1186 ||| -RRB-
.  ||| S:1186 E:1188 ||| .
FMS  ||| S:1188 E:1192 ||| NNP
subjects  ||| S:1192 E:1201 ||| NNS
had  ||| S:1201 E:1205 ||| VBD
significantly  ||| S:1205 E:1219 ||| RB
higher  ||| S:1219 E:1226 ||| RBR
serum  ||| S:1226 E:1232 ||| JJ
IL-8  ||| S:1232 E:1237 ||| CD
levels  ||| S:1237 E:1244 ||| NNS
than  ||| S:1244 E:1249 ||| IN
did  ||| S:1249 E:1253 ||| VBD
the  ||| S:1253 E:1257 ||| DT
healthy  ||| S:1257 E:1265 ||| JJ
controls  ||| S:1265 E:1274 ||| NNS
( ||| S:1274 E:1275 ||| -LRB-
327.9±588.7  ||| S:1275 E:1287 ||| FW
vs.  ||| S:1287 E:1291 ||| FW
76.4±90.5 ||| S:1291 E:1300 ||| FW
,  ||| S:1300 E:1302 ||| ,
p ||| S:1302 E:1303 ||| NNS
( ||| S:1303 E:1304 ||| -LRB-
adj ||| S:1304 E:1307 ||| LS
) ||| S:1307 E:1308 ||| -RRB-
=0.041 ||| S:1308 E:1314 ||| CD
) ||| S:1314 E:1315 ||| -RRB-
.  ||| S:1315 E:1317 ||| .
However ||| S:1317 E:1324 ||| RB
,  ||| S:1324 E:1326 ||| ,
there  ||| S:1326 E:1332 ||| EX
were  ||| S:1332 E:1337 ||| VBD
no  ||| S:1337 E:1340 ||| DT
significant  ||| S:1340 E:1352 ||| JJ
differences  ||| S:1352 E:1364 ||| NNS
in  ||| S:1364 E:1367 ||| IN
serum  ||| S:1367 E:1373 ||| CD
IL-1β ||| S:1373 E:1378 ||| CD
,  ||| S:1378 E:1380 ||| ,
IL-6 ||| S:1380 E:1384 ||| NNP
,  ||| S:1384 E:1386 ||| ,
VEGF ||| S:1386 E:1390 ||| NNP
,  ||| S:1390 E:1392 ||| ,
or  ||| S:1392 E:1395 ||| CC
NOx  ||| S:1395 E:1399 ||| JJ
levels  ||| S:1399 E:1406 ||| NNS
between  ||| S:1406 E:1414 ||| IN
the  ||| S:1414 E:1418 ||| DT
FMS  ||| S:1418 E:1422 ||| NNP
patients  ||| S:1422 E:1431 ||| NNS
and  ||| S:1431 E:1435 ||| CC
the  ||| S:1435 E:1439 ||| DT
controls  ||| S:1439 E:1448 ||| NNS
( ||| S:1448 E:1449 ||| -LRB-
p ||| S:1449 E:1450 ||| FW
( ||| S:1450 E:1451 ||| -LRB-
adj ||| S:1451 E:1454 ||| LS
) ||| S:1454 E:1455 ||| -RRB-
> ||| S:1455 E:1456 ||| CD
0.05  ||| S:1456 E:1461 ||| CD
of  ||| S:1461 E:1464 ||| IN
all ||| S:1464 E:1467 ||| DT
) ||| S:1467 E:1468 ||| -RRB-
.  ||| S:1468 E:1470 ||| .
Serum  ||| S:1470 E:1476 ||| NNP
IL-8  ||| S:1476 E:1481 ||| NNP
level  ||| S:1481 E:1487 ||| NN
did  ||| S:1487 E:1491 ||| VBD
not  ||| S:1491 E:1495 ||| RB
correlate  ||| S:1495 E:1505 ||| VBN
with  ||| S:1505 E:1510 ||| IN
PWV  ||| S:1510 E:1514 ||| NNP
and  ||| S:1514 E:1518 ||| CC
AIx  ||| S:1518 E:1522 ||| JJ
in  ||| S:1522 E:1525 ||| IN
FMS  ||| S:1525 E:1529 ||| NNP
patients ||| S:1529 E:1537 ||| NNS
.  ||| S:1537 E:1539 ||| .
This  ||| S:1539 E:1544 ||| DT
study  ||| S:1544 E:1550 ||| NN
demonstrates  ||| S:1550 E:1563 ||| VBZ
higher  ||| S:1563 E:1570 ||| JJR
AIx  ||| S:1570 E:1574 ||| JJ
and  ||| S:1574 E:1578 ||| CC
IL-8  ||| S:1578 E:1583 ||| CD
levels  ||| S:1583 E:1590 ||| NNS
in  ||| S:1590 E:1593 ||| IN
FMS  ||| S:1593 E:1597 ||| NNP
subjects  ||| S:1597 E:1606 ||| VBZ
compared  ||| S:1606 E:1615 ||| VBN
to  ||| S:1615 E:1618 ||| TO
those  ||| S:1618 E:1624 ||| DT
of  ||| S:1624 E:1627 ||| IN
the  ||| S:1627 E:1631 ||| DT
controls ||| S:1631 E:1639 ||| NNS
.  ||| S:1639 E:1641 ||| .
However ||| S:1641 E:1648 ||| RB
,  ||| S:1648 E:1650 ||| ,
arterial  ||| S:1650 E:1659 ||| JJ
stiffness  ||| S:1659 E:1669 ||| NNS
including  ||| S:1669 E:1679 ||| VBG
AIx  ||| S:1679 E:1683 ||| JJ
in  ||| S:1683 E:1686 ||| IN
FMS  ||| S:1686 E:1690 ||| NNP
was  ||| S:1690 E:1694 ||| VBD
not  ||| S:1694 E:1698 ||| RB
determined  ||| S:1698 E:1709 ||| VBN
by  ||| S:1709 E:1712 ||| IN
the  ||| S:1712 E:1716 ||| DT
serum  ||| S:1716 E:1722 ||| JJ
IL-8  ||| S:1722 E:1727 ||| CD
level ||| S:1727 E:1732 ||| NN
.  ||| S:1732 E:1734 ||| .
